{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"RNA","limit":50},"count":13,"signals":[{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":63,"context":"ty risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of approved labeling or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition. | | |  |  |  |  As an organization, we have never submitted an Investigational New Drug Application (IND)","filed_date":"2026-02-26","accession":"0001193125-26-077105","full_text":"https://origin.rootz.global/static/filing/0001193125-26-077105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"irectors | | **Executive Officers** **Kathleen Gallagher** has served as the Companys CEO since December 2025. Ms. Gallagher is also a member of the Companys Board of Directors. Ms. Gallagher will be appointed as the Companys President in connection with the Distribution. Ms. Gallagher joined Avidity in April 2021 and has served as Chief Program Officer since September 2024. Ms. Gallagher previously held the roles of Senior Vice Pr","filed_date":"2026-02-26","accession":"0001193125-26-077105","full_text":"https://origin.rootz.global/static/filing/0001193125-26-077105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":84,"context":"and regulatory examinations as well as information gathering requests, inquiries and investigations. As of the date of this Quarterly Report, there were no such matters which we believe would have a material adverse impact on our business, operating results or financial condition. Item 1A. Risk Factors. You should carefully consider the following risk factors, together with the other information contained in this Quart","filed_date":"2026-08-13","accession":"0001193125-26-349488","full_text":"https://origin.rootz.global/static/filing/0001193125-26-349488.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ubmissions by comparable foreign regulatory authorities, for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials; | | |  |  |  |  successful enrollment of study subjects in clinical trials and completion of clinical trials, in accordance with applicable regulatory and scientific standards including Good Clinical Practices (GCPs) with favorable re","filed_date":"2026-02-26","accession":"0001193125-26-077105","full_text":"https://origin.rootz.global/static/filing/0001193125-26-077105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"and development program. Our research and development costs may vary significantly depending on factors such as:  the number and scope of ongoing preclinical studies and clinical trials;  patient enrollment and trial site costs;  regulatory requirements and safety monitoring;  manufacturing scale-up and process validation activities; and  the stage of development and success of our product candidates","filed_date":"2026-08-13","accession":"0001193125-26-349488","full_text":"https://origin.rootz.global/static/filing/0001193125-26-349488.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":45,"match_count":5,"context":"e located in San Diego, California and it operates in one segment. Agreement and Plan of Merger & Separation and Distribution Agreement  In October 2025, Avidity entered into an Agreement and Plan of Merger with Novartis AG (Novartis) and Ajax Acquisition Sub, Inc., a wholly owned subsidiary of Novartis (Merger Sub), pursuant to which Merger Sub merged with and into Avidity (the Merger), with Avidity survivi","filed_date":"2026-08-13","accession":"0001193125-26-349488","full_text":"https://origin.rootz.global/static/filing/0001193125-26-349488.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":8,"match_count":1,"context":"uding the Transition Services Agreement (as defined in the Merger Agreement) and the Merger Agreement, the **Transaction Documents**), pursuant to which, among other things, the parties agreed to the separation of the SpinCo Business and SpinCo Assets, on the one hand, and the RemainCo Business and RemainCo Assets, on the other hand (each as defined in the Separation and Distribution Agreement);  **WHEREAS**,","filed_date":"2026-02-27","accession":"0001193125-26-083227","full_text":"https://origin.rootz.global/static/filing/0001193125-26-083227.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":8,"match_count":1,"context":"rity breach or other incident, whether real or perceived, could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval effo","filed_date":"2026-02-26","accession":"0001193125-26-077105","full_text":"https://origin.rootz.global/static/filing/0001193125-26-077105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":8,"match_count":1,"context":"anizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The do","filed_date":"2026-02-26","accession":"0001193125-26-077105","full_text":"https://origin.rootz.global/static/filing/0001193125-26-077105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"icacy, success, positioning and advancement of our clinical program for ATR 1072 for the treatment of PRKAG2 syndrome pursuant to our IND application, including the expected timing of initiation, enrollment, dosing, availability of data and completion of Corventis, our Phase 1/2 clinical trial evaluating ATR 1072; the study design and conduct of Corventis; the disease-modifying potential of ATR 1072","filed_date":"2026-07-14","accession":"0001193125-26-303393","full_text":"https://origin.rootz.global/static/filing/0001193125-26-303393.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":8,"match_count":1,"context":"other cybersecurity incident, whether real or perceived, could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval effo","filed_date":"2026-08-13","accession":"0001193125-26-349488","full_text":"https://origin.rootz.global/static/filing/0001193125-26-349488.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":8,"match_count":1,"context":"anizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The do","filed_date":"2026-08-13","accession":"0001193125-26-349488","full_text":"https://origin.rootz.global/static/filing/0001193125-26-349488.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RNA","company":"Atrium Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"linical trials for product candidates; the expected development, advancement and clinical evaluation of ATR 1072 for the treatment of PRKAG2 syndrome, including the expected timing of initiation, enrollment, dosing and availability of data from Corventis; the disease-modifying potential of ATR 1072 to treat PRKAG2 syndrome; our expectations regarding our RNA delivery platform and ability to generate","filed_date":"2026-08-13","accession":"0001193125-26-349482","full_text":"https://origin.rootz.global/static/filing/0001193125-26-349482.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"abf872db06faf5bed3bb1530cf0ed50cd7507beed221264ca7cac0b713f21453","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"3f3c1ed534f9506bec2c74adce84dc7af15ef8ce09aa3cf1268146c8968d77b5","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":15,"hourly_limit":500,"remaining":485,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}